Chronic News and Research

RSS

TLR4/MD-2 protein complex triggers morphine-induced inflammation

A University of Colorado Boulder-led research team has discovered that two protein receptors in the central nervous system team up to respond to morphine and cause unwanted neuroinflammation, a finding with implications for improving the efficacy of the widely used painkiller while decreasing its abuse potential.

3 Apr 2012

NutraGene introduces first ever commercial type 2 diabetes genetic test

With the launch of the country's first ever commercial genetic test for type 2 diabetes, Indians will now have access to clinically relevant and cost effective genetic risk assessment services. NutraGene, a Delhi based genomics company that launched the tests believes that its type 2 diabetes genetic test will provide physicians an effective tool in assessing the risk of diabetes in the Indian population and will help in implementing personalized prevention and management strategies.

3 Apr 2012

UCB receives FDA approval for Neupro to treat idiopathic Parkinson's, RLS

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome.

3 Apr 2012

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

ARIAD Pharmaceuticals, Inc. today announced the presentation of new preclinical data on its investigational pan-BCR-ABL inhibitor, ponatinib, and its investigational dual EGFR-ALK inhibitor, AP26113, at the American Association for Cancer Research Annual Meeting in Chicago.

3 Apr 2012

Scientists discover new serine protease: NSP4

Neutrophil granulocytes comprise important defences for the immune system. When pathogenic bacteria penetrate the body, they are the first on the scene to mobilise other immune cells via signal molecules, thereby containing the risk. To this end, they release serine proteases - enzymes that cut up other proteins to activate signal molecules. Scientists at the Max Planck Institute of Neurobiology in Martinsried have now discovered a new serine protease: neutrophil serine protease 4, or NSP4.

3 Apr 2012

Merck announces data from ZOSTAVAX Phase III study on shingles

Merck, known as MSD outside the United States and Canada, announced today that data from the pivotal Phase III study with ZOSTAVAX(Zoster Vaccine Live) in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases.

3 Apr 2012

Regular walking regimen can benefit cancer survivors

Researchers have affirmed that pancreatic cancer patients can literally take a step-by-step approach to combat fatigue. A study published in the April issue of the Journal of the American College of Surgeons reports that patients who underwent an operation as part of their cancer treatment and then started a regular walking regimen experienced less fatigue than cancer survivors who did not do the walking program.

2 Apr 2012

Study identifies specific chemical in smokeless tobacco products that induces oral cancer

The chemical (S)-N'-nitrosonornicotine, or (S)-NNN, which is present in smokeless tobacco products, is a strong oral carcinogen, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012

Rare T follicular helper cells essential for developing antibody responses to infectious agents

The characterisation of a rare immune cell's involvement in antibody production and ability to 'remember' infectious agents could help to improve vaccination and lead to new treatments for immune disorders, say researchers from the Walter and Eliza Hall Institute.

2 Apr 2012

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.

2 Apr 2012

AlloCure closes $25 million Series B venture financing

AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced the closing of a $25 million Series B venture financing.

2 Apr 2012

New guidelines offer guidance on how and when to switch between RA drug classes

A trend toward more aggressive treatment in patients just starting to develop rheumatoid arthritis is among the most important changes in treatment guidelines for the disease, according to updated American College of Rheumatology recommendations published today in the journal Arthritis Care & Research. The trend may proceed from emerging opinions that joint damage caused by RA is irreversible, and that early, intensive therapy better preserves physical function, quality of life and capacity to work.

2 Apr 2012

Novartis achieves primary endpoints in all three of QVA149 Phase III studies on COPD

Sosei Group Corporation, confirms the information released today by Novartis that the first three QVA149 Phase III studies in the treatment of chronic obstructive pulmonary disease (COPD) all met their primary endpoints.

2 Apr 2012

Childhood onset temporal lobe epilepsy has a significant impact on brain aging

New research confirms that childhood onset temporal lobe epilepsy has a significant impact on brain aging. Study findings published in Epilepsia, a peer-reviewed journal of the International League Against Epilepsy (ILAE), show age-accelerated ventricular expansion outside the normal range in this patient population.

2 Apr 2012

Rare immune cells found to play a major role in lasting immunity

According to the latest research from the Walter and Eliza Hall Institute the characterization of a rare immune cell’s involvement in antibody production and ability to ‘remember’ infectious agents could help to improve vaccination and lead to new treatments for immune disorders.

1 Apr 2012

Long delays for persistent pain management

An article in the Australian Medical Journal reveals that taxpayers are paying $34 billion a year to treat persistent pain. Pain specialist Dr Timothy Semple, and president of the Australian Pain Society, told the Herald Sun chronic back pain, arthritis, nerve injuries and people who needed care after surviving cancer made up significant numbers.

1 Apr 2012

New ACR guidelines recommend use of topical NSAIDs for older patients with knee OA

The American College of Rheumatology (ACR) Subcommittee on Osteoarthritis Guidelines has approved and issued several updates to clinical practice guidelines for the treatment of osteoarthritis (OA).

31 Mar 2012

ASI to present innovative technology solutions at ASA's Aging in America conference

Anthurium Solutions, Inc. (ASI), a technology and solutions company offering turnkey and custom in-the-cloud solutions that enable new health care delivery models, will present during the American Society on Aging (ASA)'s Aging in America, the largest multidisciplinary aging conference in the country.

31 Mar 2012

Starvation during childhood may increase risk of heart complications

Russians born during the Leningrad Siege in World War II, which was responsible for some of the greatest losses of civilian life in history, are giving scientists new strategies to identify people who experienced intrauterine growth restriction (IUGR) and starvation during childhood at greatest risk of developing long term heart complications.

31 Mar 2012

Nmnat enzyme plays a critical role in nerve injury

A new animal model of nerve injury has brought to light a critical role of an enzyme called Nmnat in nerve fiber maintenance and neuroprotection.

31 Mar 2012

Chronic News and Research

TLR4/MD-2 protein complex triggers morphine-induced inflammation

NutraGene introduces first ever commercial type 2 diabetes genetic test

UCB receives FDA approval for Neupro to treat idiopathic Parkinson's, RLS

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

Scientists discover new serine protease: NSP4

Merck announces data from ZOSTAVAX Phase III study on shingles

Regular walking regimen can benefit cancer survivors

Study identifies specific chemical in smokeless tobacco products that induces oral cancer

Rare T follicular helper cells essential for developing antibody responses to infectious agents

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

AlloCure closes $25 million Series B venture financing

New guidelines offer guidance on how and when to switch between RA drug classes

Novartis achieves primary endpoints in all three of QVA149 Phase III studies on COPD

Childhood onset temporal lobe epilepsy has a significant impact on brain aging

Rare immune cells found to play a major role in lasting immunity

Long delays for persistent pain management

New ACR guidelines recommend use of topical NSAIDs for older patients with knee OA

ASI to present innovative technology solutions at ASA's Aging in America conference

Starvation during childhood may increase risk of heart complications

Nmnat enzyme plays a critical role in nerve injury

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News